Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you've taken one dose of Mounjaro and decided to stop, the most likely outcome is that the medicine leaves your system over the next few weeks without lasting harm. Tirzepatide has a half-life of roughly five days, so stopping after a single 2.5mg dose means meaningful drug levels will have cleared within two to three weeks. That said, your body may still notice the change. What you experience — and what to do about it — depends on why you're stopping, and that question is worth sitting with before you make a final decision. These are prescription medicines assessed by a clinician for your specific situation, and any change in how you use them is worth discussing with your prescriber rather than acting on alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen of Mounjaro delivers a 2.5mg dose, a starting amount chosen specifically to let your digestive system adjust, not to produce significant weight loss. At this stage, the medicine has begun binding to GIP and GLP-1 receptors, slowing gastric emptying and nudging appetite signals, but these effects are modest at the lowest dose. If you stop now, your body hasn't undergone any lasting physiological change. The receptors return to their baseline behaviour as the drug clears.
The five-day half-life means concentrations halve roughly every five days. After two weeks, most people have very little tirzepatide left circulating. You might notice your appetite returning, digestion speeding up again, or bloating is one of the things some people experience as their digestion readjusts after stopping Mounjaro, though others feel no different at all. Neither response is unusual.
One checking habit worth building into this period: weigh yourself at the same time on the same day each week, in the same clothes or none. A consistent snapshot takes less than a minute and gives you (and your prescriber) something concrete to look at if you decide to restart. You can find more about the wider picture of what happens after stopping Mounjaro across different timeframes.
Side effects are the most common reason people consider stopping in the first week. Nausea, loose stools, fatigue and a heavy, full feeling are all reported early on, and they can feel alarming if you weren't expecting them. The NHS medicines page for tirzepatide notes that these effects are usually most noticeable after the first dose or a dose increase, and tend to settle within a few days to two weeks as your system adjusts.
If the side effects were severe (particularly any persistent, intense stomach pain that spreads to the back) you should seek medical advice promptly rather than simply stopping and waiting. The MHRA issued guidance in January 2026 flagging acute pancreatitis as a rare but serious risk with GLP-1 medicines; that symptom pattern warrants a call to 111 or your GP, not a watch-and-wait approach.
For milder discomfort, many people find that small, frequent meals, staying well hydrated and avoiding very fatty foods make week one considerably more manageable. If you didn't know any of that before your first injection, it's worth knowing now, because it might change whether stopping is actually necessary. Read about the broader topic of stopping Mounjaro for context on different circumstances and what they typically involve.
Stopping a prescription medicine after one dose is not dangerous in the way that stopping some long-term medications suddenly can be, tirzepatide doesn't require a taper to come off safely. But the decision has consequences worth thinking through with clinical input. Your prescriber can review whether a different approach to the first few weeks might resolve whatever prompted the thought of stopping. They can also note the decision in your record, which matters if you want to go back on it later.
At nume, a real clinician reviews every consultation and every repeat, so if you reach out via our contact page, you're not submitting a form into a void. Our clinical team can advise on whether pausing makes more sense than stopping entirely, whether a timing or dietary adjustment might help, and what to expect in either direction.
If cost was part of the calculation, it's worth understanding what the Mounjaro price landscape looks like across providers (including what a legitimate price should include) before deciding that treatment isn't viable. There's no obligation to continue, but an informed decision is a better one. You can also explore our weight-loss treatments page to understand the full range of clinically supervised options if Mounjaro turns out not to be right for you at this point.
Stopping after one week doesn't close any doors permanently. The medicine hasn't built up in your system, so there's no extended washout period needed before you could begin again. Clinically, you'd restart from the 2.5mg dose (the same as anyone beginning for the first time) and go through the same escalation process. This is true whether you restart a few weeks later or several months down the line.
What does matter is that any restart involves a fresh clinical assessment. Your circumstances, weight and any relevant health changes since stopping will all form part of that picture. The prescriber needs to be satisfied that treatment is still appropriate, which is why the process of going back on Mounjaro after stopping involves more than simply re-ordering. That's a patient-safety measure, not a bureaucratic hurdle.
If you want a broader grounding in the medicine itself before deciding anything, the tirzepatide overview covers how it works, what it's licensed for and what the clinical evidence shows, straightforwardly, without the pressure of a sales page. Understanding what you were taking is a reasonable place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.